Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 7/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944812 | 0.93 | KCNH2 (0.55) | SMN1; SMN2BCHEKCNH2HRH3S1PR5 | |
| SCHEMBL396677 | 0.88 | KCNH2 (0.61) | SMN1; SMN2BCHEKCNH2S1PR5S1PR4 | |
| SCHEMBL14554032 | 0.87 | BCHE (0.66) | SMN1; SMN2BCHE | |
| SCHEMBL14217826 | 0.87 | BCHE (0.66) | SMN1; SMN2BCHE | |
| SCHEMBL9492760 | 0.86 | KCNH2 (0.64) | BCHEKCNH2S1PR5S1PR4S1PR1 | |
| SCHEMBL31549853 | 0.86 | KCNH2 (0.64) | BCHEKCNH2S1PR5S1PR4S1PR1 | |
| SCHEMBL31549845 | 0.86 | KCNH2 (0.64) | BCHEKCNH2S1PR5S1PR4S1PR1 | |
| SCHEMBL9493891 | 0.86 | KCNH2 (0.64) | BCHEKCNH2S1PR5S1PR4S1PR1 | |
| SCHEMBL6216002 | 0.86 | KCNH2 (0.64) | BCHEKCNH2S1PR5S1PR4S1PR1 | |
| SCHEMBL9494162 | 0.86 | KCNH2 (0.64) | BCHEKCNH2S1PR5S1PR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | SMN1; SMN2 4085/4885BCHE 2486/4885KCNH2 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.